Cargando…
Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
Adalimumab (ADA) is applied to induce remission in patients with Crohn's disease (CD) naïve to chimeric anti-tumor necrosis factor-α (anti-TNF-α), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granulocyte and monocyte apheresis (GMA) depletes eleva...
Autores principales: | Ozeki, Keiji, Tanida, Satoshi, Mizoshita, Tsutomu, Tsukamoto, Hironobu, Ebi, Masahide, Mori, Yoshinori, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551391/ https://www.ncbi.nlm.nih.gov/pubmed/23341799 http://dx.doi.org/10.1159/000346312 |
Ejemplares similares
-
Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015) -
Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014) -
The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015) -
Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016) -
Managing refractory Crohn’s disease: challenges and solutions
por: Tanida, Satoshi, et al.
Publicado: (2015)